Cooperative benefit for the combination of rapamycin and imatinib in tuberous sclerosis complex neoplasia
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-824X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Cooperative benefit for the combination of rapamycin and imatinib in tuberous sclerosis complex neoplasia ; volume:4 ; number:1 ; day:5 ; month:7 ; year:2012 ; pages:1-7 ; date:12.2012
Vascular cell ; 4, Heft 1 (5.7.2012), 1-7, 12.2012
- Creator
-
Govindarajan, Baskaran
Willoughby, Laura
Band, Hamid
Curatolo, Adam S.
Veledar, Emir
Chen, Suephy
Bonner, Michael Y.
Abel, Martin-Garrido
Moses, Marsha A.
Arbiser, Jack L.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/2045-824X-4-11
- URN
-
urn:nbn:de:101:1-2021082906554953543032
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
20.08.2025, 1:33 PM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Govindarajan, Baskaran
- Willoughby, Laura
- Band, Hamid
- Curatolo, Adam S.
- Veledar, Emir
- Chen, Suephy
- Bonner, Michael Y.
- Abel, Martin-Garrido
- Moses, Marsha A.
- Arbiser, Jack L.
- SpringerLink (Online service)
Other Objects (12)
Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model
Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial
Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models
Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779
Inhibition of the mechanistic target of rapamycin induces cell survival via MAPK in tuberous sclerosis complex
Optimization, Formulation, and Stability of Topical Rapamycin Used for Rare Tuberous Sclerosis Disease: from Ointment to Liposomes
Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis
Translatome analysis of tuberous sclerosis complex 1 patient-derived neural progenitor cells reveals rapamycin-dependent and independent alterations
Topical Rapamycin for Facial Angiofibromas in a Child with Tuberous Sclerosis Complex (TSC): A Case Report and Long-Term Follow-up
Intraepithelial neoplasia
Focal gigantism in tuberous sclerosis
Differentiation and neoplasia
Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model
Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial
Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models
Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779
Inhibition of the mechanistic target of rapamycin induces cell survival via MAPK in tuberous sclerosis complex
Optimization, Formulation, and Stability of Topical Rapamycin Used for Rare Tuberous Sclerosis Disease: from Ointment to Liposomes
Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis
Translatome analysis of tuberous sclerosis complex 1 patient-derived neural progenitor cells reveals rapamycin-dependent and independent alterations
Topical Rapamycin for Facial Angiofibromas in a Child with Tuberous Sclerosis Complex (TSC): A Case Report and Long-Term Follow-up
Intraepithelial neoplasia
Focal gigantism in tuberous sclerosis
Differentiation and neoplasia
Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model
Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial
Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models
Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779
Inhibition of the mechanistic target of rapamycin induces cell survival via MAPK in tuberous sclerosis complex
Optimization, Formulation, and Stability of Topical Rapamycin Used for Rare Tuberous Sclerosis Disease: from Ointment to Liposomes
Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis
Translatome analysis of tuberous sclerosis complex 1 patient-derived neural progenitor cells reveals rapamycin-dependent and independent alterations
Topical Rapamycin for Facial Angiofibromas in a Child with Tuberous Sclerosis Complex (TSC): A Case Report and Long-Term Follow-up
Intraepithelial neoplasia
Focal gigantism in tuberous sclerosis